Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer

Background: Zongertinib is a novel, oral, HER2-selective tyrosine kinase inhibitor (TKI) that spares wild-type EGFR. While it has a favorable safety profile, severe cutaneous adverse events (scAEs) can occur, especially in the post-immunotherapy setting. Case presentation: A 55-year-old female with...

Description complète

Détails bibliographiques

Auteurs principaux:	Kodai Kawamura, Kaori Kubota, Kazuya Ichikado
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2026-01-01
Collection:	Respiratory Medicine Case Reports
Sujets:	Zongertinib HER2-Mutant non-small cell lung cancer Drug eruption Erythema multiforme Re-challenge Tyrosine kinase inhibitor
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S221300712600081X
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!